An Introduction to Stroke
Most strokes (85%) are caused by acute ischaemia due to blockage of a cerebral artery, leading to loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral or subarachnoid haemorrhage. Treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytics and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. Increasingly, oral anticoagulants are preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia (e.g. transplantation of mesenchymal stem cells) are also emerging as potentially useful.
Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.
Arlene Wilkie, ESO-WSO 2020 – Stroke Action Plan for Europe
We were delighted to have an opportunity to hear all about the Stroke Action Plan for Europe from Arlene Wilkie, Director General of the Stroke Alliance for Europe (SAFE). Related useful resources: Stroke Alliance for Europe (SAFE) Economic Impact of Stroke in Europe Questions What are the major challenges in stroke care across Europe and […]
Patent Foramen Ovale Closure—Addressing the Unmet Need for Reducing the Risk of Ischemic Stroke
US Neurology. 2020;16(1):54–60 DOI: https://doi.org/10.17925/USN.2020.16.1.54
Globally, a high proportion (around 25%) of transient ischemic attacks (TIAs) and ischemic strokes are cryptogenic.1,2 The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification defines a cryptogenic stroke as a brain infarction that is not caused by definite cardioembolism, large artery atherosclerosis, or small artery disease, despite extensive investigations.3 The “ASCOD” classification defines strokes […]
Anna Tancin Lambert, EAN 2020 – Atrial Fibrillation and Cryptogenic Stroke in the NOR-FIB Study
Anna Tancin Lambert (University of Oslo and Department of Neurology Østfold Hospital Trust, Norway) discussed with us exciting interim findings from the international, multicentre, prospective, observational Nordic Atrial Fibrillation and Stroke (NOR-FIB) study, which highlight atrial fibrillation as the hidden cause of cryptogenic stroke (ClinicalTrials.gov Identifier: NCT02937077). Questions 1. What proportion of stroke and transient […]
Acute Stroke Imaging in the Era of the DAWN, DEFUSE 3 and WAKE-UP Study Findings
European Neurological Review. 2019:14(1):24–7. DOI: https://doi.org/10.17925/ENR.2019.14.1.24
In 2018, two randomised controlled trials, DAWN (the Clinical Mismatch in the Triage of Wake up and Late Presenting Strokes Undergoing Neurointervention with Trevo Thrombectomy Procedure) and DEFUSE 3 (Endovascular Therapy Following Imaging Evaluation for Ischaemic Stroke 3), implemented computed tomography (CT) and magnetic resonance imaging (MRI) in patients with stroke.1,2 These studies showed the […]
Ulrich Dirnagl, EAN 2019 – Charles Edouard Brown-Séquard Lecture
The Charles Edouard Brown-Séquard Lecture at EAN 2019 was delivered by Prof. Ulrich Dirnagl, who had a chat with EAN eCommunciations Board Co-Chair, PD DR. Tim von Oertzen about his work. Video produced by and shared with kind authorisation of the European Academy of Neurology (EAN 2019).
Jeffrey L Saver & Natan Bornstein, ESOC 2019 – ImpACT-24B
Trial investigators Jeffrey L Saver and Natan Bornstein share results and insights from the Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window (ImpACT-24B; NCT00826059). The aim of this international, randomised, double-blind, sham-controlled, pivotal trial was to determine whether sphenopalatine ganglion stimulation 8-24 h after acute ischaemic stroke improved […]
Nikola Sprigg, ESOC 2019 – TICH-2
Nikola Sprigg, Principal Investigator of the Tranexamic acid for IntraCerebral Haemorrhage 2 (TICH-2) trial (ISRCTN93732214), which previously reported that tranexamic acid does not improve outcome in adults with stroke due to intracerebral haemorrhage despite reducing haematoma expansion, shares results and insights from one-year follow up data. Content produced in Milan, Italy and shared with kind authorisation […]
Masatoshi Koga & Manabu Inoue, ESOC 2019 – THAWS trial
Trial investigators Masatoshi Koga and Manabu Inoue discuss results from THAWS (NCT02002325), an investigator-initiated Japanese multicentre randomised controlled clinical trial designed to clarify the efficacy and safety of MRI-based intravenous thrombolysis with alteplase for patients with acute wake-up ischaemic stroke and those having acute ischaemic stroke with unknown time of symptom onset. Content produced in […]
Tom Moullaali, ESOC 2019 – Pooled individual patient data analyses of the INTERACT2 and ATACH-II trials
Tom Moullaali discusses results of pooled individual patient data analyses of the INTERACT2 (NCT00716079) and ATACH-II (NCT01176565) trials, the two largest studies of blood pressure control in acute intracerebral haemorrhage. The aim of the meta-analysis was to ascertain whether systolic blood pressure parameters are associated with better clinical outcomes. Content produced in Milan, Italy and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!